Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/50283
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Baruchel, Sylvain | por |
dc.contributor.author | Sharp, Julia R. | por |
dc.contributor.author | Bartels, Ute | por |
dc.contributor.author | Hukin, Juliette | por |
dc.contributor.author | Odame, Isaac | por |
dc.contributor.author | Portwine, Carol | por |
dc.contributor.author | Strother, Doug | por |
dc.contributor.author | Fryer, Chris | por |
dc.contributor.author | Reis, R. M. | por |
dc.contributor.author | Martinho, Olga | por |
dc.contributor.other | [et al.] | - |
dc.date.accessioned | 2018-02-09T12:54:30Z | - |
dc.date.available | 2018-02-09T12:54:30Z | - |
dc.date.issued | 2009-09 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://hdl.handle.net/1822/50283 | - |
dc.description.abstract | PURPOSE: To evaluate the safety, efficacy and pharmacokinetics of imatinib in children with recurrent or refractory central nervous system (CNS) tumours expressing KIT and/or PDGFRA. METHODS: Nineteen patients aged 2-18 years, with recurrent or refractory CNS tumours expressing either of the target receptors KIT and/or PDGFRA (by immunohistochemistry) were eligible. Participants received imatinib orally at a dose of 440 mg/m(2)/day and toxicities and tumour responses were monitored. Serial blood and cerebrospinal fluid samples for pharmacokinetics were obtained in a subset of consenting patients. Frozen tumour samples were analysed retrospectively for KIT and PDGFRA gene amplification in a subset of patients for whom samples were available. RESULTS: Common toxicities were lymphopaenia, neutropaenia, leucopaenia, elevated serum transaminases and vomiting. No intratumoural haemorrhages were observed. Although there were no objective responses to imatinib, four patients had long-term stable disease (SD) (38-104 weeks). Our results suggest a possible relationship between KIT expression and maintenance of SD with imatinib treatment; KIT immunopositivity was seen in only 58% (11/19) of study participants overall, but in 100% of patients with SD at 38 weeks. All patient tumours showed PDGFRA expression. Pharmacokinetic data showed a high interpatient variability, but corresponded with previously reported values. CONCLUSIONS: Imatinib at 440 mg/m(2)/day is relatively safe in children with recurrent CNS tumours, but induced no objective responses. Demonstration of SD in previously progressing patients (KIT-expressing) suggests cytostatic activity of imatinib. | por |
dc.language.iso | eng | por |
dc.publisher | Elsevier | por |
dc.rights | openAccess | por |
dc.subject | Imatinib | por |
dc.subject | Paediatrics | por |
dc.subject | Phase II | por |
dc.subject | Central nervous system neoplasms | por |
dc.subject | Brain neoplasms | por |
dc.subject | Platelet-derived growth factor alpha receptor | por |
dc.subject | C-kit | por |
dc.subject | Drug toxicity | por |
dc.subject | Pharmacokinetics | por |
dc.title | A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours | por |
dc.type | article | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0959804909003487 | por |
oaire.citationStartPage | 2352 | por |
oaire.citationEndPage | 2359 | por |
oaire.citationIssue | 13 | por |
oaire.citationVolume | 45 | por |
dc.date.updated | 2018-01-17T14:01:56Z | - |
dc.identifier.doi | 10.1016/j.ejca.2009.05.008 | por |
dc.identifier.pmid | 19505817 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | European Journal of Cancer | por |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
baruchel s_ eur j cancer 2009.pdf | 141,46 kB | Adobe PDF | Ver/Abrir |